Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH

（actually not combination product, but have to select that option in order to delete warning in "study desine"）MDT method for sNH with the description as follow： 1. diagnosis of neonatal hemolysis：

The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they met one criterion from Category A or two criteria from Category B:

Category A:

• Positive DAT
• Significantly elevated ETCOc;
• Significant morphological abnormalities

Category B:

• Positive release test;
• Elevated ETCOc;
• COHb > 1.2%;
• Hb < 140 g/L or Hct) < 40%;
• Ret > 6%. 2.Exchange transfusion (ET) therapy for sNH： any of the following criteria are met:

(1) TSB ≥ the current ET threshold; (2) TSB > (ET - 2) mg/dL or the increase of TSB > 0.5 mg/dL/h, accompanied by abnormal aEEG findings; (3) TSB > (ET - 2) mg/dL or > 0.5 mg/dL/h, accompanied by a BIND score of 4-6; (4) Presence of clinical manifestations of acute ABE; (5) BIND score of 7-9.

Control (current) method for sNH (severe neonatal hemolysis) with the description as follow：

• Diagnosis of neonatal hemolysis： The neonatal subjects with symptom of hyperbilirubinemia are diagnosed as hemolysis if they have positive Direct Antiglobulin Test (DAT) or positive release test result.
• Exchange transfusion (ET) therapy for sNH： The neonatal subjects with symptom of hyperbilirubinemia are treated with ET therapy if their Total serum bilirubin (TSB) reaches or exceeds the current exchange transfusion threshold;